Pharmaceutical Research Institute, 8 Rydygiera St., Warszawa 01-793, Poland.
Bioorg Med Chem Lett. 2012 Oct 1;22(19):6103-7. doi: 10.1016/j.bmcl.2012.08.032. Epub 2012 Aug 15.
Novel indolo[2,3-b]quinoline derivatives substituted at N-6 and C-2 or C-9 positions with (dimethylamino)ethyl chains linked to heteroaromatic core by ether, amide or amine bonds, were manufactured and evaluated in vitro for their cytotoxic activity against several cell lines of different origin including multidrug resistant sublines and tested for their ability to influence the cell cycle and inhibit topoisomerase II activity. It was found, that all compounds show cytotoxic activity against cell lines tested, including multidrug resistant LoVo/DX, MES-SA/DX5 and HL-60 sublines. The tested compounds induce the G(2)M phase cell cycle arrest in Jurkat cells, and inhibit topoisomerase II activity.
新型吲哚并[2,3-b]喹啉衍生物在 N-6 和 C-2 或 C-9 位置被(二甲氨基)乙基链取代,通过醚、酰胺或胺键连接到杂芳环核心上,被合成并评估了它们对不同来源的几种细胞系的体外细胞毒性活性,包括多药耐药亚系,并测试了它们影响细胞周期和抑制拓扑异构酶 II 活性的能力。结果发现,所有化合物对测试的细胞系均显示细胞毒性活性,包括多药耐药 LoVo/DX、MES-SA/DX5 和 HL-60 亚系。测试的化合物在 Jurkat 细胞中诱导 G(2)M 期细胞周期阻滞,并抑制拓扑异构酶 II 活性。